Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB

Arbutus Biopharma Corp

Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.
Arbutus now holds global rights to imdusiran; reports 8 patients achieved functional cure in Phase 2a trials IM-PROVE I/II to date.
New Scientific Advisory Board formed with five HBV experts to advise on late-stage clinical development of cHBV pipeline.

item 1.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.